ENHANCED BIOCOMPATIBLE NON-POROUS BLOOD OXYGENATORS

增强型生物相容性无孔血氧发生器

• 批准号: 6141764
• 负责人: John J Bowser
• 金额: $ 10万
• 依托单位: COMPACT MEMBRANE SYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-01 至 2002-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6141764
• 关键词: artificial membranes; biomaterial compatibility; biotechnology; blood oxygenator; oxygen transport; polymers; surface coating; technology /technique development

Membrane based blood oxygenators are successfully used for cardiopulmonary by-pass (CPB) surgery. A number of programs are evaluating long-term membrane based blood oxygenators for artificial lungs and acute respiratory distress syndrome (ARDS). For both short- term use (CPB) and long-term use (ARDS), there is a need for enhanced blood compatible surfaces. Examples of two coating systems that are presently used to enhance blood compatibility are Avecor's Trillium and Medtronic's Carmeda. While both of these systems have some success in enhancing blood compatibility, the success is limited. Also, they tend to reduce gas (oxygen) flux and most importantly they are prone to wetting out. Compact Membrane Systems (CMS) proposes the development of a novel non-porous surface having excellent (1) wet-out resistance, (2) gas flux, and (3) blood compatibility. Enhanced blood compatibility will be based on known blood biocompatible systems. In Phase I, CMS will develop these novel structures and demonstrate enhanced performance in an in-vitro environment. PROPOSED COMMERCIAL APPLICATIONS: Successful completion of this project will significantly improve the treatment of the 500,000 CPB surgeries per year. It will also be a cornerstone in improving the potential of long-term therapy associated with ARDS.

基于膜的血氧剂成功地用于心肺旁通（CPB）手术。许多程序正在评估人造肺和急性呼吸窘迫综合征（ARDS）的长期基于膜的血氧剂。对于短期使用（CPB）和长期使用（ARD），需要增强血液兼容的表面。目前用于增强血液兼容性的两个涂料系统的例子是Avecor的Trillium和Medtronic的Carmeda。尽管这两个系统在增强血液兼容性方面都有一定的成功，但成功是有限的。而且，它们倾向于减少气体（氧）通量，最重要的是，它们容易弄湿。紧凑型膜系统（CMS）提出了具有出色（1）湿阻力，（2）气体通量和（3）血液兼容性的新型非孔表面的发展。增强的血液兼容性将基于已知的血液生物相容性系统。在第一阶段，CMS将开发这些新颖的结构，并在体外环境中表现出增强的性能。拟议的商业申请：该项目的成功完成将显着改善每年500,000个CPB手术的治疗。这也将是提高与ARDS相关的长期治疗潜力的基石。